Related Experiment Video
Updated: Jul 14, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Practical guidelines for diagnostic use of in vitro chemosensitivity tests
Timo Schinköthe1, Svenja Haeger, Mariano R Gabri
1TumorTec GmbH, Eupener Str. 148, 50933 Cologne, Germany.
Anticancer Research
|June 28, 2007
Summary
Chemotherapy sensitivity and resistance assays (CSRAs) aim to personalize cancer treatment. This report identifies essential criteria for developing clinically applicable CSRAs to guide effective chemotherapy selection for patients.
Area of Science:
- Oncology
- Pharmacology
- Clinical Diagnostics
Background:
- Numerous chemotherapy sensitivity and resistance assays (CSRAs) exist to test drug efficacy on patient tumor samples in vitro.
- The goal of CSRAs is to enable personalized cancer treatment strategies.
- A 2004 ASCO review concluded that no existing CSRAs were suitable for routine clinical practice.
Purpose of the Study:
- To evaluate the indispensable criteria for chemotherapy sensitivity and resistance assays (CSRAs) to be broadly applicable in clinical routine.
- To define requirements for CSRAs to provide meaningful treatment recommendations for current and future cytostatic drugs.
Main Methods:
- Review and analysis of existing literature on chemotherapy sensitivity and resistance assays (CSRAs).
- Examination of technical requirements for clinical applicability and future-proofing of assays.
Main Results:
- Established that chemotherapy sensitivity and resistance assays (CSRAs) must meet specific technical criteria for clinical adoption.
- Highlighted the need for assays to be relevant for both current and emerging chemotherapy agents.
Conclusions:
- Defines the essential criteria for developing robust and clinically relevant chemotherapy sensitivity and resistance assays (CSRAs).
- Emphasizes the importance of assay standardization and validation for effective personalized cancer therapy.
